| pubmed-article:21115905 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21115905 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:21115905 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:21115905 | lifeskim:mentions | umls-concept:C0909825 | lld:lifeskim |
| pubmed-article:21115905 | lifeskim:mentions | umls-concept:C1413473 | lld:lifeskim |
| pubmed-article:21115905 | lifeskim:mentions | umls-concept:C0909826 | lld:lifeskim |
| pubmed-article:21115905 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:21115905 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:21115905 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:21115905 | pubmed:dateCreated | 2010-11-30 | lld:pubmed |
| pubmed-article:21115905 | pubmed:abstractText | Because human claudin-3 and claudin-4 (CLDN3 and CLDN4) are overexpressed in a variety of carcinomas, they are promising targets for cancer therapy. The aim of the present study was to generate a dual-targeting monoclonal antibody against CLDN3 and CLDN4 and evaluate its antitumour activity. | lld:pubmed |
| pubmed-article:21115905 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21115905 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115905 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21115905 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115905 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115905 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115905 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21115905 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21115905 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:21115905 | pubmed:issn | 1791-7530 | lld:pubmed |
| pubmed-article:21115905 | pubmed:author | pubmed-author:MarkG PGP | lld:pubmed |
| pubmed-article:21115905 | pubmed:author | pubmed-author:AndoHiroshiH | lld:pubmed |
| pubmed-article:21115905 | pubmed:author | pubmed-author:NakamuraKazuy... | lld:pubmed |
| pubmed-article:21115905 | pubmed:author | pubmed-author:FuruyaAkikoA | lld:pubmed |
| pubmed-article:21115905 | pubmed:author | pubmed-author:KawamotoShino... | lld:pubmed |
| pubmed-article:21115905 | pubmed:author | pubmed-author:SuzukiMasayoM | lld:pubmed |
| pubmed-article:21115905 | pubmed:author | pubmed-author:Kato-NakanoMa... | lld:pubmed |
| pubmed-article:21115905 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21115905 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:21115905 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21115905 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21115905 | pubmed:pagination | 4555-62 | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:meshHeading | pubmed-meshheading:21115905... | lld:pubmed |
| pubmed-article:21115905 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:21115905 | pubmed:articleTitle | Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4. | lld:pubmed |
| pubmed-article:21115905 | pubmed:affiliation | Antibody Research Laboratories, Kyowa Hakko Kirin Co Ltd, Tokyo, Japan. | lld:pubmed |
| pubmed-article:21115905 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21115905 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
